Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Incretin-based antihyperglycemic therapies increase intestinal mucosal expansion and polyp growth in mouse models. We aimed to evaluate the effect of dipeptidyl peptidase-4 inhibitors (DPP-4i) or glucagon-like peptide-1 receptor agonists (GLP-1ra) initiation on colorectal cancer incidence. We conducted a cohort study on US Medicare beneficiaries over age 66 from 2007 to 2013 without prevalent cancer. We identified three active-comparator and new-user cohorts: DPP-4i versus thiazolidinediones (TZD), DPP-4i versus sulphonylureas (SU), and GLP-1ra versus long acting insulin (LAI). Follow-up started from 6 months post-second prescription and ended 6 months after stopping (primary as-treated analysis). We estimated hazard ratios (HR) and 95 % confidence intervals (CI) for incident colorectal cancer adjusting for measured confounders using propensity score weighting. The median duration of treatment ranged 0.7–0.9 years among DPP-4i cohorts. Based on 104 events among 39,334 DPP-4i and 63 events among 25,786 TZD initiators, there was no association between DPP-4i initiation and colorectal cancer (adjusted HR = 1.17 (CI 0.88, 1.71)). There were 73 events among 27,047 DPP-4i and 266 events among 76,012 SU initiators with the adjusted HR 0.98 (CI 0.74, 1.30). We identified 5600 GLP-1ra and 54,767 LAI initiators and the median duration of treatment was 0.8 and 1.2 years, respectively. The adjusted HR was 0.82 (CI 0.42, 1.58) based on <11 events among GLP-1ra versus 276 events among LAI initiators. Although limited by the short duration of treatment, our analyses based on real-world drug utilization patterns provide evidence of no short-term effect of incretin-based agents on colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 2×
“Introduction Incretin-based therapies, glucagon-like peptide-1 receptor agonists (GLP-1ra) and dipeptidyl peptidase-4 inhibitors (DPP-4i), are commonly used second line therapies in the management of type 2 diabetes mellitus (DM) [1].”
BackgroundSelf-citationEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577 · cited 2×
“Furthermore, large-scale cardiovascular outcome trials have been completed demonstrating no substantial safety concerns, particularly with market-leading sitagliptin [6-8].”
BackgroundSelf-citationAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646 · cited 1×
“The major strength of our study is the utilization of the active comparator, new user, cohort study design, which restricts the study population to initiators of therapies with similar indication [12, 24].”
MethodLund, J. L., Richardson, D. B., & Stürmer, T. (2015) · Current Epidemiology Reports · doi:10.1007/s40471-015-0053-5 · Cited by 739 · cited 4×
“The major strength of our study is the utilization of the active comparator, new user, cohort study design, which restricts the study population to initiators of therapies with similar indication [12, 24].”
BackgroundMethodInfluentialSelf-citationGLP-1 receptor agonists: a review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Ellis, S. L. (2015) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814559725 · Cited by 282
GLP-1R Agonists Promote Normal and Neoplastic Intestinal Growth through Mechanisms Requiring Fgf7
Koehler, J. A., Baggio, L. L., Yusta, B., Longuet, C., Rowland, K. J., Cao, X., Holland, D., Brubaker, P. L., & Drucker, D. J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.02.005 · Cited by 133 · cited 1×
“In mouse studies, exenatide was observed to increase small intestinal growth over 14–16 weeks after treatment and stimulated growth factor expression in colon polyps [9].”
Background
Cited by
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
Nauck, M. A., Jensen, T. J., Rosenkilde, C., Calanna, S., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc17-1825 · Cited by 94
Self-citationWang, J., & Kim, C. H. (2022) · Endocrine Research · doi:10.1080/07435800.2021.1955255 · Cited by 74
“For example, Htoo et al.(23) investigated patients with US Medicare beneficiaries and found the adjusted hazard ratio for colon cancer was 0.”
BackgroundInfluentialOverbeek, J. A., Bakker, M., van der Heijden, A. A. W. A., van Herk‐Sukel, M. P. P., Herings, R. M. C., & Nijpels, G. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3004 · Cited by 71
“The full texts of the remaining studies were evaluated for the inclusion and exclusion criteria, which resulted in a final inclusion of 25 studies.(2,3,17-39) For 4 studies, the authors were contacted, because the publications did not contain sufficient information regarding risk or variables needed to calculate the r…”
BackgroundMa, B., Wang, X., Ren, H., Li, Y., Zhang, H., Yang, M., & Li, J. (2023) · BMC Cancer · doi:10.1186/s12885-023-11077-w · Cited by 36
Metadata
- Authors
- Htoo, P. T., Buse, J. B., Gokhale, M., Marquis, M. A., Pate, V., & Stürmer, T.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2016-05-10
- Volume
- 72
- Issue
- 8
- Pages
- 1013-1023
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2357833390
- Cited by
- 25
- References
- 7
- FWCI
- 2.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors. https://app.cochat.ai/papers/10.1007/s00228-016-2068-3
- The paper
- Htoo, P. T., Buse, J. B., Gokhale, M., Marquis, M. A., Pate, V., & Stürmer, T. (2016). Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-016-2068-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.